

David A Cowan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/673165/publications.pdf>

Version: 2024-02-01

122
papers

3,087
citations

159585

30
h-index

206112

48
g-index

124
all docs

124
docs citations

124
times ranked

2776
citing authors

#	ARTICLE	IF	CITATIONS
1	Ambient ionization mass spectrometry applied to new psychoactive substance analysis. <i>Mass Spectrometry Reviews</i> , 2023, 42, 3-34.	5.4	15
2	Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration. <i>Drug Testing and Analysis</i> , 2022, 14, 808-819.	2.6	7
3	Stability of drugs of abuse in synthetic oral fluid investigated using a simple dilute and inject method of analysis. <i>Drug Testing and Analysis</i> , 2022, , .	2.6	1
4	Combined statistical decision limits based on two GH-2000 scores for the detection of growth hormone misuse. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1439-1448.	1.5	2
5	A miniaturized passive sampling-based workflow for monitoring chemicals of emerging concern in water. <i>Science of the Total Environment</i> , 2022, 839, 156260.	8.0	10
6	Comparison of normal distribution-based and nonparametric decision limits on the GH-2000 score for detecting growth hormone misuse (doping) in sport. <i>Biometrical Journal</i> , 2021, 63, 187-200.	1.0	4
7	Artificial oral fluid characterisation: Potential for use as a reference matrix in drug testing. <i>Drug Testing and Analysis</i> , 2021, 13, 709-719.	2.6	2
8	Rapid direct analysis of river water and machine learning assisted suspect screening of emerging contaminants in passive sampler extracts. <i>Analytical Methods</i> , 2021, 13, 595-606.	2.7	17
9	Towards identifying nicomorphine administration in doping control: synthesis of metabolites. <i>Bioanalysis</i> , 2021, 13, 1415-1425.	1.5	0
10	Advances in the detection of growth hormone releasing hormone synthetic analogs. <i>Drug Testing and Analysis</i> , 2021, 13, 1871-1887.	2.6	10
11	Evidence of enzyme-mediated transesterification of synthetic cannabinoids with ethanol: potential toxicological impact. <i>Forensic Toxicology</i> , 2020, 38, 95-107.	2.4	5
12	Antidoping analysis: a special focus. <i>Bioanalysis</i> , 2020, 12, 707-709.	1.5	1
13	Determination of anabolic steroids in dried blood using microsampling and gas chromatography-tandem mass spectrometry: Application to a testosterone gel administration study. <i>Journal of Chromatography A</i> , 2020, 1628, 461445.	3.7	18
14	Isolation, detection and identification of synthetic cannabinoids in alternative formulations or dosage forms. <i>Forensic Chemistry</i> , 2020, 18, 100227.	2.8	13
15	Inter-Laboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured Intact by Mass Spectrometry. <i>Clinical Chemistry</i> , 2020, 66, 579-586.	3.2	17
16	In Vitro Phase I Metabolic Profiling of the Synthetic Cannabinoids AM-694, 5F-NNEI, FUB-APINACA, MFUBINAC, and AMB-FUBINACA. <i>Chemical Research in Toxicology</i> , 2020, 33, 1653-1664.	3.3	10
17	Evaluation of combined sewer overflow impacts on short-term pharmaceutical and illicit drug occurrence in a heavily urbanised tidal river catchment (London, UK). <i>Science of the Total Environment</i> , 2019, 657, 1099-1111.	8.0	61
18	Exact statistical calculation of the uncertainty term in the decision limits of the GH-2000 score for growth hormone misuse (doping) detection. <i>Statistical Methods in Medical Research</i> , 2019, 28, 928-936.	1.5	4

#	ARTICLE	IF	CITATIONS
19	Hyperandrogenism controversy in elite women's sport: an examination and critique of recent evidence. <i>British Journal of Sports Medicine</i> , 2018, 52, 1481-1482.	6.7	31
20	Peptide selection for the quantification of P α III α CNP in human serum by mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2018, 32, 535-542.	1.5	6
21	A correction to the age-adjustment of the GH-2000 score used in the detection of growth hormone misuse. <i>BMC Research Notes</i> , 2018, 11, 650.	1.4	4
22	IRMS delta values ($¹³C$) of nandrolone and testosterone products available in the UK: Implications for anti-doping. <i>Drug Testing and Analysis</i> , 2018, 10, 1722-1727.	2.6	16
23	Why do endocrine profiles in elite athletes differ between sports?. <i>Clinical Diabetes and Endocrinology</i> , 2018, 4, 3.	2.7	18
24	Novel markers to detect recombinant human insulin-like growth factor (rhIGF)/rhIGF binding protein (rhIGFBP) misuse in athletes. <i>Drug Testing and Analysis</i> , 2017, 9, 30-37.	2.6	4
25	Rapid Analysis of Anabolic Steroid Metabolites in Urine by Combining Field Asymmetric Waveform Ion Mobility Spectrometry with Liquid Chromatography and Mass Spectrometry. <i>Analytical Chemistry</i> , 2017, 89, 7431-7437.	6.5	29
26	Direct Monitoring of Exogenous \hat{I}^3 -Hydroxybutyric Acid in Body Fluids by NMR Spectroscopy. <i>Analytical Chemistry</i> , 2017, 89, 8343-8350.	6.5	31
27	Increases in Serum Growth Hormone Concentrations Associated with GHB Administration. <i>Journal of Analytical Toxicology</i> , 2017, 41, 54-59.	2.8	7
28	Evaluation of longitudinal steroid profiles from male football players in UEFA competitions between 2008 and 2013. <i>Drug Testing and Analysis</i> , 2016, 8, 603-612.	2.6	13
29	Use and misuse of hormones in sport. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 882-883.	11.4	6
30	Statistical methodology for age-adjustment of the GH-2000 score detecting growth hormone misuse. <i>BMC Medical Research Methodology</i> , 2016, 16, 147.	3.1	6
31	LC-MS-Based Metabolomics Discovers Purine Endogenous Associations with Low-Dose Salbutamol in Urine Collected for Antidoping Tests. <i>Analytical Chemistry</i> , 2016, 88, 2243-2249.	6.5	16
32	Determining the authenticity of athlete urine in doping control by DNA analysis. <i>Drug Testing and Analysis</i> , 2015, 7, 912-918.	2.6	9
33	Medical and Ethical Concerns Regarding Women With Hyperandrogenism and Elite Sport. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 825-827.	3.6	26
34	The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor and amino-terminal pro-peptide of type III collagen assays. <i>Drug Testing and Analysis</i> , 2015, 7, 745-755.	2.6	26
35	Artificial neural network modelling of pharmaceutical residue retention times in wastewater extracts using gradient liquid chromatography-high resolution mass spectrometry data. <i>Journal of Chromatography A</i> , 2015, 1396, 34-44.	3.7	46
36	Potent and untested drugs sold as "dietary supplements". <i>BMJ</i> , The, 2015, 351, h4181.	6.0	3

#	ARTICLE	IF	CITATIONS
37	Signal enhancement of glucuronide conjugates in LC-MS/MS by derivatization with the phosphonium propylamine cation tris(trimethoxyphenyl) phosphonium propylamine, for forensic purposes. <i>Drug Testing and Analysis</i> , 2014, 6, 500-505.	2.6	6
38	Multidimensional LC-MS/MS Enables Simultaneous Quantification of Intact Human Insulin and Five Recombinant Analogs in Human Plasma. <i>Analytical Chemistry</i> , 2014, 86, 694-702.	6.5	79
39	Biochemical Markers of Insulin-Like Growth Factor-I Misuse in Athletes: The Response of Serum IGF-I, Procollagen Type III Amino-Terminal Propeptide, and the GH-2000 Score to the Administration of rhIGF-I/rhIGF Binding Protein-3 Complex. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2259-2268.	3.6	14
40	Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry. <i>Clinical Chemistry</i> , 2014, 60, 541-548.	3.2	96
41	Quantification of intact human insulin-like growth factor-I in serum by nano-ultrahigh-performance liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1426-1432.	1.5	30
42	The effects of two weeks of recombinant growth hormone administration on the response of IGF-I and N-terminal pro-peptide of collagen type III (P-III-NP) during a single bout of high resistance exercise in resistance trained young men. <i>Growth Hormone and IGF Research</i> , 2013, 23, 76-80.	1.1	6
43	Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9669-9683.	3.7	17
44	Prediction of Chromatographic Retention Time in High-Resolution Anti-Doping Screening Data Using Artificial Neural Networks. <i>Analytical Chemistry</i> , 2013, 85, 10330-10337.	6.5	54
45	Steroids excreted in urine by neonates with 21-hydroxylase deficiency. 4. Characterization, using GC-MS and GC-MS/MS, of 11oxo-pregnanes and 11oxo-pregnenes. <i>Steroids</i> , 2013, 78, 468-475.	1.8	13
46	21-Hydroxylase deficiency in the neonate - trends in steroid anabolism and catabolism during the first weeks of life. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 334-347.	2.5	15
47	Detection of ketamine and its metabolites in human hair using an integrated nanoflow liquid chromatography column and electrospray emitter fritted with a single porous 10 μ m bead. <i>Journal of Chromatography A</i> , 2013, 1277, 1-6.	3.7	17
48	Comparison of reversed-phase and hydrophilic interaction liquid chromatography for the quantification of ephedrines using medium-resolution accurate mass spectrometry. <i>Journal of Chromatography A</i> , 2013, 1289, 37-46.	3.7	43
49	Use of ultra-high pressure liquid chromatography coupled to high resolution mass spectrometry for fast screening in high throughput doping control. <i>Journal of Chromatography A</i> , 2013, 1288, 82-95.	3.7	73
50	Metabolic Phenotype of the Healthy Rodent Model Using In-Vial Extraction of Dried Serum, Urine, and Cerebrospinal Fluid Spots. <i>Analytical Chemistry</i> , 2013, 85, 7257-7263.	6.5	15
51	Measurement of Ethyl Glucuronide, Ethyl Sulphate and Their Ratio in the Urine and Serum of Healthy Volunteers after Two Doses of Alcohol. <i>Alcohol and Alcoholism</i> , 2013, 48, 74-82.	1.6	34
52	Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. <i>Drug Testing and Analysis</i> , 2013, 5, 843-849.	2.6	11
53	Investigation of microbore UPLC and nontraditional mobile phase compositions for bioanalytical LC-MS/MS. <i>Bioanalysis</i> , 2012, 4, 1287-1297.	1.5	25
54	Pharmacokinetic Properties of \hat{A} -Hydroxybutyrate (GHB) in Whole Blood, Serum, and Urine. <i>Journal of Analytical Toxicology</i> , 2012, 36, 88-95.	2.8	63

#	ARTICLE	IF	CITATIONS
55	Investigation of basic mobile phases with positive ESI LC-MS for metabonomics studies. <i>Bioanalysis</i> , 2012, 4, 2833-2842.	1.5	6
56	Steroids excreted in urine by neonates with 21-hydroxylase deficiency. 2. Characterization, using GC-MS and GC-MS/MS, of pregnanes and pregnenes with an oxo-group on the A- or B-ring. <i>Steroids</i> , 2012, 77, 382-393.	1.8	22
57	The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. <i>Growth Hormone and IGF Research</i> , 2012, 22, 53-58.	1.1	32
58	Steroids excreted in urine by neonates with 21-hydroxylase deficiency. 3. Characterization, using GC-MS and GC-MS/MS, of androstanes and androstenes. <i>Steroids</i> , 2012, 77, 1487-1501.	1.8	16
59	Incorporating cutting-edge analytical science research into anti-doping testing. <i>Science and Justice - Journal of the Forensic Science Society</i> , 2012, 52, 135.	2.1	0
60	The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes. <i>Drug Testing and Analysis</i> , 2012, 4, 455-459.	2.6	12
61	Comparison of reversed-phase and hydrophilic interaction liquid chromatography for the separation of ephedrines. <i>Journal of Chromatography A</i> , 2012, 1228, 329-337.	3.7	41
62	Comprehensive investigation of the influence of acidic, basic, and organic mobile phase compositions on bioanalytical assay sensitivity in positive ESI mode LC/MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 59, 138-150.	2.8	43
63	A molecularly imprinted receptor for separation of testosterone and epitestosterone, based on a steroidal cross-linker. <i>Steroids</i> , 2011, 76, 478-483.	1.8	28
64	Synthesis of N-oxide derivatives of metyrapone and their detection as in vitro metabolites*. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 33, 309-312.	2.4	12
65	Metabolites of lorazepam: Relevance of past findings to present day use of LC-MS/MS in analytical toxicology. <i>Drug Testing and Analysis</i> , 2011, 3, 695-704.	2.6	4
66	A simple and rapid pre-confirmation method to distinguish endogenous human haemoglobin from synthetic haemoglobin-based oxygen carriers in doping control. <i>Electrophoresis</i> , 2011, 32, 2915-2918.	2.4	5
67	A simple high pH liquid chromatography-tandem mass spectrometry method for basic compounds: Application to ephedrines in doping control analysis. <i>Journal of Chromatography A</i> , 2011, 1218, 2098-2105.	3.7	23
68	The Quest for Clean Competition in Sports: Are the Testers Catching the Dopers?. <i>Clinical Chemistry</i> , 2011, 57, 943-947.	3.2	7
69	Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (ecstasy): is metabolism a contributory factor?. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1357-1363.	2.4	38
70	A rapid screening LC-MS/MS method based on conventional HPLC pumps for the analysis of low molecular weight xenobiotics: application to doping control analysis. <i>Drug Testing and Analysis</i> , 2010, 2, 311-322.	2.6	20
71	The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF, type 3 pro-collagen (P α 1 β) and the GH-2000 detection score. <i>Clinical Endocrinology</i> , 2010, 72, 520-526.	2.4	43
72	Urinary $\hat{3}$ -Hydroxybutyrate Concentrations in 1126 Female Subjects. <i>Journal of Analytical Toxicology</i> , 2010, 34, 555-561.	2.8	29

#	ARTICLE	IF	CITATIONS
73	The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes. <i>European Journal of Endocrinology</i> , 2010, 163, 45-54.	3.7	25
74	A new marker for early diagnosis of 21-hydroxylase deficiency: 3 β ,16 α ,17 α -trihydroxy-5 β -pregnane-7,20-dione. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 121, 574-581.	2.5	14
75	Steroids excreted in urine by neonates with 21-hydroxylase deficiency: Characterization, using GC-MS and GC-MS/MS, of the D-ring and side chain structure of pregnanes and pregnenes. <i>Steroids</i> , 2010, 75, 34-52.	1.8	34
76	Serum Insulin-Like Growth Factor-I and Pro-Collagen Type III N-Terminal Peptide in Adolescent Elite Athletes: Implications for the Detection of Growth Hormone Abuse in Sport. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2969-2976.	3.6	21
77	Use of Human Microsomes and Deuterated Substrates: An Alternative Approach for the Identification of Novel Metabolites of Ketamine by Mass Spectrometry. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1769-1778.	3.3	54
78	Influence of ethnicity on IGF-I and procollagen III peptide (P α 11 β) in elite athletes and its effect on the ability to detect GH abuse. <i>Clinical Endocrinology</i> , 2009, 70, 161-168.	2.4	42
79	Subject-based profiling for the detection of testosterone administration in sport. <i>Drug Testing and Analysis</i> , 2009, 1, 22-24.	2.6	15
80	Counterfeiting in performance- and image-enhancing drugs. <i>Drug Testing and Analysis</i> , 2009, 1, 135-142.	2.6	63
81	A determination of the pre-analytical storage conditions for insulin like growth factor-I and type III procollagen peptide. <i>Growth Hormone and IGF Research</i> , 2009, 19, 43-50.	1.1	18
82	Laboratory issues in the implementation of the marker method. <i>Growth Hormone and IGF Research</i> , 2009, 19, 357-360.	1.1	22
83	Moving one step closer to catching the GH cheats: The GH-2004 experience. <i>Growth Hormone and IGF Research</i> , 2009, 19, 346-351.	1.1	12
84	Doping in sport ² . Quantification of the impurity 19-norandrostenedione in pharmaceutical preparations of norethisterone. <i>Steroids</i> , 2009, 74, 335-340.	1.8	12
85	Doping in sport ¹ . Excretion of 19-norandrosterone by healthy women, including those using contraceptives containing norethisterone. <i>Steroids</i> , 2009, 74, 329-334.	1.8	18
86	Doping in sport: 3. Metabolic conversion of oral norethisterone to urinary 19-norandrosterone. <i>Steroids</i> , 2009, 74, 341-349.	1.8	11
87	Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 876, 137-142.	2.3	93
88	Liquid chromatographic-mass spectrometric analysis of glucuronide-conjugated anabolic steroid metabolites: method validation and interlaboratory comparison. <i>Journal of Mass Spectrometry</i> , 2008, 43, 965-973.	1.6	55
89	Sodium ascorbate improves yield of urinary steroids during hydrolysis with <i>Helix pomatia</i> juice. <i>Steroids</i> , 2008, 73, 309-319.	1.8	31
90	Ion trap MS/MS of intact testosterone and epitestosterone conjugates ² Adducts, fragile ions and the advantages of derivatisation. <i>Steroids</i> , 2008, 73, 621-628.	1.8	13

#	ARTICLE	IF	CITATIONS
91	Physical Effects of Short-Term Recombinant Human Growth Hormone Administration in Abstinent Steroid Dependency. <i>Hormone Research in Paediatrics</i> , 2008, 69, 343-354.	1.8	36
92	The Effect of Sports Injury on Insulin-Like Growth Factor-I and Type 3 Procollagen: Implications for Detection of Growth Hormone Abuse in Athletes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2760-2763.	3.6	35
93	Drug testing. <i>Essays in Biochemistry</i> , 2008, 44, 139-148.	4.7	5
94	Recombinant Human Growth Hormone in Abstinent Androgenic-Anabolic Steroid Use: Psychological, Endocrine and Trophic Factor Effects. <i>Current Neurovascular Research</i> , 2007, 4, 9-18.	1.1	14
95	Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users. <i>Growth Hormone and IGF Research</i> , 2007, 17, 201-209.	1.1	9
96	Short-term recombinant human growth hormone administration improves respiratory function in abstinent anabolic-androgenic steroid users. <i>Growth Hormone and IGF Research</i> , 2007, 17, 328-335.	1.1	21
97	Detection of the Administration of Human Erythropoietin (HuEPO) to Canines. <i>Journal of Analytical Toxicology</i> , 2006, 30, 663-669.	2.8	11
98	Testosterone Measurement by Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry: Validation of a Method for Routine Clinical Practice. <i>Clinical Chemistry</i> , 2005, 51, 1472-1479.	3.2	139
99	Effects of Oral Administration of Androstenedione on Plasma Androgens in Young Women Using Hormonal Contraception. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6030-6038.	3.6	13
100	MALDI TOF Post-Source Decay Investigation of Alkali Metal Adducts of Apolar Polypentylresorcinol Dendrimers. <i>Macromolecules</i> , 2003, 36, 8297-8303.	4.8	20
101	Effect of Androstenedione Ingestion on Plasma Testosterone in Young Women; a Dietary Supplement with Potential Health Risks. <i>Clinical Chemistry</i> , 2003, 49, 167-169.	3.2	28
102	Enhanced Affinity Capture MALDI-TOF MS: Orientation of an Immunoglobulin G Using Recombinant Protein G. <i>Analytical Chemistry</i> , 2002, 74, 3677-3683.	6.5	91
103	Candida albicans in Urine Can Produce Testosterone: Impact on the Testosterone/Epitestosterone Sports Drug Test. <i>Clinical Chemistry</i> , 2002, 48, 1799-1801.	3.2	19
104	Speciation of Fe(III)-chelate complexes by electrospray ionization ion trap and laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2002, 16, 1556-1561.	1.5	23
105	Synthesis of a dendron and dendrimer consisting of MALDI matrix like branching units. <i>Tetrahedron Letters</i> , 2002, 43, 6723-6727.	1.4	7
106	The effect of 3,4-methylenedioxymethamphetamine (MDMA, ?ecstasy?) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. <i>British Journal of Pharmacology</i> , 2002, 135, 649-656.	5.4	68
107	Properties and units in the clinical laboratory sciences. Part XII. Properties and units in clinical pharmacology and toxicology (Technical Report) (IFCC-IUPAC 1999). <i>Pure and Applied Chemistry</i> , 2000, 72, 479-552.	1.9	11
108	Stereospecific Analysis and Enantiomeric Disposition of 3,4-Methylenedioxymethamphetamine (Ecstasy) in Humans. <i>Clinical Chemistry</i> , 1999, 45, 1058-1069.	3.2	106

#	ARTICLE	IF	CITATIONS
109	Adrenal and gonadal contributions to urinary excretion and plasma concentration of epitestosterone in men - effect of adrenal stimulation and implications for detection of testosterone abuse. <i>Clinical Endocrinology</i> , 1999, 50, 661-668.	2.4	19
110	Discrimination of mammalian growth hormones by peptide-mass mapping. <i>Rapid Communications in Mass Spectrometry</i> , 1998, 12, 975-981.	1.5	5
111	Low-dose MDMA (‘ecstasy’) induces vasopressin secretion. <i>Lancet, The</i> , 1998, 351, 1784.	13.7	130
112	Properties and units in the clinical laboratory sciences VI. Properties and units in IOC prohibited drugs (Technical Report). <i>Pure and Applied Chemistry</i> , 1997, 69, 1081-1136.	1.9	8
113	Doping in Sport: Misuse, Analytical Tests, and Legal Aspects. <i>Clinical Chemistry</i> , 1997, 43, 1110-1113.	3.2	30
114	Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. <i>Clinical Endocrinology</i> , 1997, 47, 43-50.	2.4	60
115	Intramuscular administration of 5 α -dihydrotestosterone heptanoate: changes in urinary hormone profile. <i>Clinical Chemistry</i> , 1997, 43, 2091-2098.	3.2	20
116	Transmission of the results of tests for International Olympic Committee-defined drugs of abuse. <i>Biomedical Applications</i> , 1996, 687, 157-182.	1.7	4
117	Tryptic mapping of human chorionic gonadotropin by matrix-assisted laser desorption/ionization mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 1995, 9, 1021-1026.	1.5	35
118	Two Assays for Dihydrocodeine in Plasma and in Urine and Their Use to Determine the Bioavailability of a Controlled-Release Product. <i>Journal of Pharmaceutical Sciences</i> , 1988, 77, 606-609.	3.3	4
119	Metabolism of 4-substituted-N-ethyl-N-methylanilines: Chromatographic and mass spectrometric identification of N-oxidation metabolic products formed in vitro. <i>Biomedical Mass Spectrometry</i> , 1982, 9, 233-240.	1.9	5
120	Metabolism of metyrapone: 2 α -chromatographic and mass spectral properties of the N-oxides of metyrapone and metyrapol. <i>Biological Mass Spectrometry</i> , 1981, 8, 270-277.	0.5	13
121	Metabolic N-oxidation of 3-substituted pyridines: Identification of products by mass spectrometry. <i>Biomedical Mass Spectrometry</i> , 1978, 5, 551-556.	1.9	38
122	Identification of Four New Metabolic Products of Metoclopramide using Mass Spectrometry. <i>Xenobiotica</i> , 1976, 6, 605-616.	1.1	21